SIM0613 in Participants With Advanced Solid Tumors

Summary

This is a multicenter, open-label, first-in-human (FIH) study to evaluate the safety, tolerability, efficacy and pharmacokinetic/pharmacodynamic characteristics of SIM0613 in participants with locally advanced/ metastatic solid tumors. The study starts with a dose escalation part (Part 1) followed by a dose expansion part (Part 2).

Timeline

Start

2026-05-15

Primary completion

2028-06

Completion

2028-12

Drugs

Indications